Federal Register of Legislation - Australian Government

Primary content

PB 10 of 2018 Determinations/Health as made
This determination amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010) to list two drugs on the Pharmaceutical Benefits Scheme (PBS), effective 1 January 2018 and are required to be determined on either F1 or F2 formulary. One listed drug is changing formulary status from Combination Drugs List to F2 with the PBS listing of a new brand. In addition, three drugs are delisting and are required to be removed from F1.
Administered by: Health
Made 29 Jan 2018
Registered 31 Jan 2018
Tabled HR 05 Feb 2018
Tabled Senate 05 Feb 2018
Date of repeal 02 Feb 2018
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

 

PB 10 of 2018

 

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated       29   January 2018

 

 

 

 

 

 

 

 

 

LISA LA RANCE

 

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 

 

Part 1         Preliminary

1              Name of Determination

         (1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 1).

         (2)   This Determination may also be cited as PB 10 of 2018.

2              Commencement

                This Determination commences on 1 February 2018.

3              Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

                Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).


Schedule 1             Amendments

 

(Section 3)

 

[1]     Schedule 1, after item dealing with Coal tar

 

Omit

 

Coal tar-prepared

 

[2]     Schedule 1, after item dealing with Cyclophosphamide

 

Omit

 

Cyproheptadine

 

[3]     Schedule 1, after item dealing with Glycomacropeptide and essential amino acids with vitamins and minerals

 

Insert

 

Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine

 

[4]     Schedule 1, after item dealing with Obinutuzumab

 

Insert

 

Ocrelizumab

 

[5]     Schedule 1, after item dealing with Ticagrelor

 

Omit

 

Ticarcillin with clavulanic acid

 

[6]     Schedule 2,

 

Insert as first item

 

Abacavir with Lamivudine